BACKGROUND: In Nigeria, it is estimated that 3.6% of the population were living with Human immunodeficiency virus in 2009, and the country had the world's second highest number of HIV/AIDS related deaths after South Africa. Viral hepatitis is also a major public health concern as hepatitis B virus (HBV) afflicts an estimated 350 million people, and hepatitis C virus (HCV) affects 150 million people worldwide. OBJECTIVES: We conducted a retrospective study of HBV and HCV seroprevalence among Nigerian population coming to our clinic in Abuja and receiving HIV/AIDS treatment. METHODS: In this cohort study, we collected medical data from 443 HIV-positive patients between September 2010 and May 2011. Standard enzyme immunoassays were used to determine the serological prevalence of hepatitis B (HBsAg) and C (anti-HCV antibody) among HIV-positive individuals. RESULTS: Among the HIV/AIDS positive individuals, we found that 35 patients were infected with hepatitis B virus (7.9%), 10 with hepatitis C virus (2.3%) and 3 with both hepatitis B and C viruses (0.7%). The overall hepatitis-HIV prevalence is 10.8%. The majority of the population infected was under 39 years of age (55%) and the same proportion of males and females was observed in all the studied categories (HIV, HIV + hepatitis B and/or C). Remarkably, an overall lower CD4 count was seen in the co-infected population (205 cells/µl versus 243 cells/µl), with the lowest seen for the triply infected individuals (97 cells/µl). CONCLUSIONS: Our findings underscore the importance of screening for hepatitis B and hepatitis C viruses in the HIV-infected population in developing countries, and particularly in sub-Saharan Africa, where the epidemics are still growing.
BACKGROUND: In Nigeria, it is estimated that 3.6% of the population were living with Human immunodeficiency virus in 2009, and the country had the world's second highest number of HIV/AIDS related deaths after South Africa. Viral hepatitis is also a major public health concern as hepatitis B virus (HBV) afflicts an estimated 350 million people, and hepatitis C virus (HCV) affects 150 million people worldwide. OBJECTIVES: We conducted a retrospective study of HBV and HCV seroprevalence among Nigerian population coming to our clinic in Abuja and receiving HIV/AIDS treatment. METHODS: In this cohort study, we collected medical data from 443 HIV-positive patients between September 2010 and May 2011. Standard enzyme immunoassays were used to determine the serological prevalence of hepatitis B (HBsAg) and C (anti-HCV antibody) among HIV-positive individuals. RESULTS: Among the HIV/AIDS positive individuals, we found that 35 patients were infected with hepatitis B virus (7.9%), 10 with hepatitis C virus (2.3%) and 3 with both hepatitis B and C viruses (0.7%). The overall hepatitis-HIV prevalence is 10.8%. The majority of the population infected was under 39 years of age (55%) and the same proportion of males and females was observed in all the studied categories (HIV, HIV + hepatitis B and/or C). Remarkably, an overall lower CD4 count was seen in the co-infected population (205 cells/µl versus 243 cells/µl), with the lowest seen for the triply infected individuals (97 cells/µl). CONCLUSIONS: Our findings underscore the importance of screening for hepatitis B and hepatitis C viruses in the HIV-infected population in developing countries, and particularly in sub-Saharan Africa, where the epidemics are still growing.
Entities:
Keywords:
Hepatitis B virus; Hepatitis C virus; Human Immunodeficiency Virus; Nigeria; cohort study
Authors: H K Monga; M C Rodriguez-Barradas; K Breaux; K Khattak; C L Troisi; M Velez; B Yoffe Journal: Clin Infect Dis Date: 2001-06-15 Impact factor: 9.079
Authors: Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Jean Jacques N Noubiap; Peter V Aka; Aubin J Nanfack; Lucy A Agyingi; Johnson N Ngai; Phillipe N Nyambi Journal: PLoS One Date: 2015-09-15 Impact factor: 3.240
Authors: Olusegun A Adeyemi; Andrew Mitchell; Ashley Shutt; Trevor A Crowell; Nicaise Ndembi; Afoke Kokogho; Habib O Ramadhani; Merlin L Robb; Stefan D Baral; Julie A Ake; Manhattan E Charurat; Sheila Peel; Rebecca G Nowak Journal: BMC Infect Dis Date: 2021-07-06 Impact factor: 3.090
Authors: Geane L Flores; Adilson J de Almeida; Juliana C Miguel; Helena M Cruz; Moyra M Portilho; Letícia de P Scalioni; Vanessa A Marques; Lia Laura Lewis-Ximenez; Elisabeth Lampe; Livia Melo Villar Journal: Int J Environ Res Public Health Date: 2016-03-11 Impact factor: 3.390
Authors: Patrick A Coffie; Boris K Tchounga; Guillaume Bado; Mathieu Kabran; Daouda K Minta; Gilles Wandeler; Geoffrey S Gottlieb; François Dabis; Serge P Eholie; Didier K Ekouevi Journal: BMC Infect Dis Date: 2017-07-04 Impact factor: 3.090